Skip to main content
. 2022 Jun 14;66(7):e00308-22. doi: 10.1128/aac.00308-22

FIG 4.

FIG 4

Long-term administration of CAMB in patients with CMC does not cause renal impairment or anemia. (a) Serum levels of creatinine and potassium (left panel) and hemoglobin (right panel) over time after initiation of CAMB treatment. Horizontal dashed lines depict the normal range of creatinine values, and horizontal dotted lines depict the normal range of potassium (left panel) and hemoglobin (right panel) values. (b) Serum levels of erythropoietin after initiation of CAMB treatment in patient 1 (day 1,214 from CAMB initiation), patient 2 (days 148, 203, and 574 from CAMB initiation), and patient 4 (days 28, 88, 220, 674, and 796 from CAMB initiation). Horizontal dotted lines depict the normal range of erythropoietin.